The stock of Adma Biologics Incorporated (NASDAQ:ADMA) registered an increase of 2.83% in short interest. ADMA’s total short interest was 138,200 shares in September as published by FINRA. Its up 2.83% from 134,400 shares, reported previously. With 45,200 shares average volume, it will take short sellers 3 days to cover their ADMA’s short positions. The short interest to Adma Biologics Incorporated’s float is 3.99%. About 32,916 shares traded hands. ADMA Biologics Inc (NASDAQ:ADMA) has risen 8.58% since February 8, 2016 and is uptrending. It has underperformed by 7.91% the S&P500.
ADMA Biologics, Inc. is a late-stage biopharmaceutical firm that develops, makes and intends to market specialty plasma biologics for the treatment and prevention of infectious diseases. The company has a market cap of $66.39 million. The Firm is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. It currently has negative earnings. The Company’s divisions include Plasma Collection Centers, which includes its activities in Georgia; Research and Development, which includes its plasma development activities in New Jersey, and Corporate.
The institutional sentiment increased to 3.6 in 2016 Q2. Its up 2.38, from 1.22 in 2016Q1. The ratio improved, as 2 funds sold all ADMA Biologics Inc shares owned while 3 reduced positions. 6 funds bought stakes while 12 increased positions. They now own 16.07 million shares or 132.36% more from 6.92 million shares in 2016Q1.
Aisling Capital Llc holds 5.07% of its portfolio in ADMA Biologics Inc for 3.61 million shares. Consonance Capital Management Lp owns 1.27 million shares or 1.07% of their US portfolio. Moreover, Broadfin Capital Llc has 0.64% invested in the company for 1.11 million shares. The New York-based Iguana Healthcare Management Llc has invested 0.3% in the stock. Perceptive Advisors Llc, a New York-based fund reported 398,394 shares.
Out of 2 analysts covering ADMA Biologics (NASDAQ:ADMA), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. ADMA Biologics has been the topic of 3 analyst reports since September 17, 2015 according to StockzIntelligence Inc. Raymond James downgraded the stock on August 1 to “Market Perform” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.